000283140 001__ 283140
000283140 005__ 20240229155049.0
000283140 0247_ $$2doi$$a10.1038/s41698-023-00453-1
000283140 0247_ $$2pmid$$apmid:37741941
000283140 0247_ $$2pmc$$apmc:PMC10517995
000283140 037__ $$aDKFZ-2023-01927
000283140 041__ $$aEnglish
000283140 082__ $$a610
000283140 1001_ $$aZhang, Jinsen$$b0
000283140 245__ $$aDistinct aneuploid evolution of astrocytoma and glioblastoma during recurrence.
000283140 260__ $$a[London]$$bSpringer Nature$$c2023
000283140 3367_ $$2DRIVER$$aarticle
000283140 3367_ $$2DataCite$$aOutput Types/Journal article
000283140 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1695708508_3632
000283140 3367_ $$2BibTeX$$aARTICLE
000283140 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000283140 3367_ $$00$$2EndNote$$aJournal Article
000283140 500__ $$aDKFZ-ZMBH Alliance
000283140 520__ $$aAstrocytoma and glioblastoma (GB) are reclassified subtypes of adult diffuse gliomas based on distinct isocitrate dehydrogenase (IDH) mutation in the fifth edition of the WHO Classification of Tumors of the Central Nervous System. The recurrence of gliomas is a common and inevitable challenge, and analyzing the distinct genomic alterations in astrocytoma and GB could provide insights into their progression. This study conducted a longitudinal investigation, utilizing whole-exome sequencing, on 65 paired primary/recurrent gliomas. It examined chromosome arm aneuploidies, copy number variations (CNVs) of cancer-related genes and pathway enrichments during the relapse. The veracity of these findings was verified through the integration of our data with multiple public resources and by corroborative immunohistochemistry (IHC). The results revealed a greater prevalence of aneuploidy changes and acquired CNVs in recurrent lower grade astrocytoma than in relapsed grade 4 astrocytoma and GB. Larger aneuploidy changes were predictive of an unfavorable prognosis in lower grade astrocytoma (P < 0.05). Further, patients with acquired gains of 1q, 6p or loss of 13q at recurrence had a shorter overall survival in lower grade astrocytoma (P < 0.05); however, these prognostic effects were confined in grade 4 astrocytoma and GB. Moreover, acquired gains of 12 genes (including VEGFA) on 6p during relapse were associated with unfavorable prognosis for lower grade astrocytoma patients. Notably, elevated VEGFA expression during recurrence corresponded to poorer survival, validated through IHC and CGGA data. To summarize, these findings offer valuable insights into the progression of gliomas and have implications for guiding therapeutic approaches during recurrence.
000283140 536__ $$0G:(DE-HGF)POF4-311$$a311 - Zellbiologie und Tumorbiologie (POF4-311)$$cPOF4-311$$fPOF IV$$x0
000283140 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000283140 7001_ $$aFeng, Yuan$$b1
000283140 7001_ $$aLi, Guanghao$$b2
000283140 7001_ $$aZhang, Jianhua$$b3
000283140 7001_ $$aZhang, Xin$$b4
000283140 7001_ $$aZhang, Yi$$b5
000283140 7001_ $$aQin, Zhiyong$$b6
000283140 7001_ $$aZhuang, Dongxiao$$b7
000283140 7001_ $$aQiu, Tianming$$b8
000283140 7001_ $$aShi, Zhifeng$$b9
000283140 7001_ $$aZhu, Wei$$b10
000283140 7001_ $$aZhang, Rui$$b11
000283140 7001_ $$aWu, Yonghe$$b12
000283140 7001_ $$0P:(DE-He78)76aeb2431f7458c9261e69c5420390c6$$aLiu, Haikun$$b13$$udkfz
000283140 7001_ $$aCao, Dandan$$b14
000283140 7001_ $$00000-0001-6409-5078$$aHua, Wei$$b15
000283140 7001_ $$aMao, Ying$$b16
000283140 773__ $$0PERI:(DE-600)2891458-2$$a10.1038/s41698-023-00453-1$$gVol. 7, no. 1, p. 97$$n1$$p97$$tnpj precision oncology$$v7$$x2397-768X$$y2023
000283140 909CO $$ooai:inrepo02.dkfz.de:283140$$pVDB
000283140 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)76aeb2431f7458c9261e69c5420390c6$$aDeutsches Krebsforschungszentrum$$b13$$kDKFZ
000283140 9131_ $$0G:(DE-HGF)POF4-311$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vZellbiologie und Tumorbiologie$$x0
000283140 9141_ $$y2023
000283140 915__ $$0LIC:(DE-HGF)CCBYNV$$2V:(DE-HGF)$$aCreative Commons Attribution CC BY (No Version)$$bDOAJ$$d2021-10-13T14:35:09Z
000283140 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2023-03-31
000283140 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2023-03-31
000283140 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2023-03-31
000283140 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2023-03-31
000283140 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2023-03-31
000283140 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bNPJ PRECIS ONCOL : 2022$$d2023-10-27
000283140 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2023-10-27
000283140 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2023-10-27
000283140 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central$$d2023-10-27
000283140 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2023-04-12T15:13:05Z
000283140 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2023-04-12T15:13:05Z
000283140 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Anonymous peer review$$d2023-04-12T15:13:05Z
000283140 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2023-10-27
000283140 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2023-10-27
000283140 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2023-10-27
000283140 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2023-10-27
000283140 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bNPJ PRECIS ONCOL : 2022$$d2023-10-27
000283140 9201_ $$0I:(DE-He78)A240-20160331$$kA240$$lA240 Molekulare Neurogenetik$$x0
000283140 980__ $$ajournal
000283140 980__ $$aVDB
000283140 980__ $$aI:(DE-He78)A240-20160331
000283140 980__ $$aUNRESTRICTED